Individual Patient Expanded Access for Acellular Tissue Engineered Vessel (ATEV) for Vascular System Injuries

Expanded access Approved for marketing Humacyte, Inc.

Summary

Individual patient expanded access requests may be considered for patients who have no other treatment options and are not eligible for an ATEV clinical study

Timeline

Start: —
Primary completion: —
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Background	Acellular Tissue Engineered Vessel (ATEV)	Unknown	—	—

Indications

No indication recorded.